Filgotinib for the treatment of Crohn's disease. (Record no. 28091109)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 01215 a2200325 4500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250517201911.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 201803s 0 0 eng d |
| 022 ## - INTERNATIONAL STANDARD SERIAL NUMBER | |
| International Standard Serial Number | 1744-7658 |
| 024 7# - OTHER STANDARD IDENTIFIER | |
| Standard number or code | 10.1080/13543784.2018.1442433 |
| Source of number or code | doi |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | NLM |
| Language of cataloging | eng |
| Transcribing agency | NLM |
| 100 1# - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Labetoulle, Remi |
| 264 #0 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Date of production, publication, distribution, manufacture, or copyright notice | 20180326 |
| 245 00 - TITLE STATEMENT | |
| Title | Filgotinib for the treatment of Crohn's disease. |
| Medium | [electronic resource] |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Name of publisher, distributor, etc. | Expert opinion on investigational drugs |
| Date of publication, distribution, etc. | Mar 2018 |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 295-300 p. |
| Other physical details | digital |
| 500 ## - GENERAL NOTE | |
| General note | Publication Type: Journal Article; Review |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Crohn Disease |
| General subdivision | drug therapy |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Disease Progression |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Gastrointestinal Agents |
| General subdivision | adverse effects |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Humans |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Janus Kinase Inhibitors |
| General subdivision | adverse effects |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Pyridines |
| General subdivision | adverse effects |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Severity of Illness Index |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Triazoles |
| General subdivision | adverse effects |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Tumor Necrosis Factor-alpha |
| General subdivision | antagonists & inhibitors |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Paul, Stephane |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Roblin, Xavier |
| 773 0# - HOST ITEM ENTRY | |
| Title | Expert opinion on investigational drugs |
| Related parts | vol. 27 |
| -- | no. 3 |
| -- | p. 295-300 |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://doi.org/10.1080/13543784.2018.1442433">https://doi.org/10.1080/13543784.2018.1442433</a> |
| Public note | Available from publisher's website |
No items available.